Market access for medical devices in Egypt involves not only product registration, but also the local applicant, import licences, shipment-by-shipment customs clearance, labelling, change management and post-market vigilance. For foreign manufacturers, selecting a suitable Egyptian applicant at the outset, confirming the applicable pathway for the product, and arranging follow-up maintenance of the registration certificate in advance all affect whether the product can enter the market and continue to be sold.
This article sets out 20 frequently asked questions on Egyptian medical device registration, based on the laws, implementing regulations and current guidelines published by the Egyptian Drug Authority (EDA). This article relies primarily on official documents. Please note in particular: some guidelines exist in different versions, and certain official documents are available only in Arabic; for specific projects, the official texts and written requirements applicable at the time of EDA acceptance prevail.
1. Regulatory Framework: Who Regulates and Who Can Apply
Q1 Who regulates medical devices in Egypt, and what is the main legal basis?
Answer: The main competent authority for medical device registration and import control in Egypt is the Egyptian Drug Authority (EDA), implemented in practice by its Central Administration of Medical Devices and the related registration, market access, inspection and safety departments.
The main regulatory framework includes:
- Establishing law: Law No. 151 of 2019, which establishes the EDA and its statutory duties.
- Implementing regulation: Prime Minister Decree No. 777 of 2020, which further clarifies the EDA’s regulatory powers and the fee items.
- Technical guidelines: The EDA issues guidelines on registration, changes, import licences, labelling, UDI and vigilance under EDREX codes, which serve as key operational references for specific submissions.
Applications related to medical device registration and import are mainly submitted through the EDA’s MeDevice electronic platform:
Legal basis: Law No. 151/2019; Prime Minister Decree No. 777/2020; EDREX: GL.CAMD.002.
Q2 Can a foreign manufacturer apply directly to the EDA for medical device registration?
Answer: As a general rule, a foreign manufacturer cannot act directly as the Egyptian registration applicant in its own name. According to the EDA medical device registration guideline, the applicants for imported products mainly include Egyptian import companies or qualifying scientific offices; locally manufactured products are applied for by the Egyptian local manufacturer.
Foreign manufacturers therefore usually need to complete registration through an Egyptian importer or scientific office that meets EDA requirements. The registration applicant, the registration notification and the local import arrangements should be clarified before the project starts.
It is important to distinguish: the foreign company is the legal manufacturer of the product, while the Egyptian local applicant is responsible for submitting the application to the EDA and carries the related regulatory obligations in Egypt; the two are not the same concept.
Legal basis: EDREX: GL.CAMD.002, Article 2 and the related application requirements.
Q3 What qualifications must an Egyptian applicant have, and what authorisation documents must the manufacturer provide?
Answer: Where an import company acts as the applicant, the following documents are typically required:
- A valid Commercial Register;
- Medical device importer registration or licensing documents;
- A valid distribution or agency contract between the foreign supplier and the Egyptian applicant;
- A registration authorisation letter issued by the legal manufacturer or its duly authorised entity; the authorisation document should clearly state the trade name of the products;
- If the authorisation is granted through a foreign distributor or supplier, evidence of the relationship between the manufacturer and that entity must also be provided, showing that it has the authority to sign contracts and grant agency rights on behalf of the manufacturer.
If a scientific office applies, the scientific office licence and the corresponding manufacturer authorisation and relationship evidence must also be provided. For products not manufactured by the parent company, the legal manufacturer’s authorisation and a letter of no objection from the parent company are usually also required.
Company representatives submitting matters to the EDA should also provide qualifying authorisation documents, and the relevant signatures must be verified through bank signature verification as required by the guideline.
Legal basis: EDREX: GL.CAMD.002, Annex 1, document requirements for applicants.
Q4 Can an Egyptian medical device registration certificate be transferred to another agent?
Answer: A registration certificate cannot be transferred simply by signing a private transfer agreement between the two parties; however, it is also wrong to assume that changing the agent necessarily means re-registration.
Special attention should be paid to the fourth edition of EDREX: GL.CAMD.003 published in November 2026. This edition provides more detailed rules on changes of the registration applicant.
For example, where the original registration applicant is a registered medical device import company and the registration notification is to be transferred to another registered import company, or to a scientific office, an application may be submitted as a change file. Where the conditions are met, after obtaining the initial acceptance number for the change file, a 3-month market circulation transition period is granted; after the transition period ends, if final approval has not yet been obtained, the products may no longer circulate. The guideline also states that an additional 3-month period may be requested upon payment of the service fee as required.
However, note that:
- Adding a new dealer or distributor is not equivalent to a transfer of the registration applicant;
- The case of adding a distributor does not enjoy the above 3-month circulation grace period; circulation under that arrangement is only allowed after final approval of the change has been obtained;
- The applicable pathway depends on the original registration holder, the intended new holder and the specific matter applied for.
Therefore, before changing the certificate holder or the agency arrangement for an Egyptian registration, the change categories in the fourth edition guideline should be checked first; simplistic conclusions such as ‘re-registration’ or ‘only changing the agent’s name’ should not be applied directly.
Legal basis: EDREX: GL.CAMD.002, Article 11 and related provisions; EDREX: GL.CAMD.003, fourth edition (November 2026).
2. Classification and Reference Countries
Q5 How are medical devices classified in Egypt, and which registration requirements does classification affect?
Answer: Medical devices in Egypt are classified into four classes according to risk level:
| Risk class | Classification description |
|---|---|
| Class I | Low risk, with sterile and non-sterile subcategories; |
| Class IIa | Low-medium risk; |
| Class IIb | Medium-high risk; |
| Class III | High risk. |
IVDs follow separate registration rules; the classification rules for general medical devices cannot be applied directly to IVDs.
Product classification affects the registration dossier, international quality certificates, review by specialist committees and post-market safety documentation requirements. For example:
- CE documents: A CE certificate is not required for non-sterile Class I medical devices, but this does not exempt the products from other registration documents.
- Products from non-reference countries: Such products may need to be reviewed by an EDA specialist scientific committee.
- Post-market safety documents: Class IIb and III devices, and Class I and IIa devices that have been subject to regulatory measures, must submit the corresponding safety documentation in line with the vigilance guideline.
- IVDs: The classification systems and their intended uses in the registration guideline and the post-market vigilance guideline must be assessed separately.
Classification should be confirmed based on the intended use, working principle, mode of contact, duration of use and risk profile of the product; it cannot be determined directly from the product name or from the classification result in another country.
Legal basis: EDREX: GL.CAMD.002; EDREX: GL.CAMD.001; EDREX: GL.CAP.Care.040.
Q6 Which reference countries does Egypt recognise? Do Chinese manufacturers belong to the reference countries?
Answer: According to the medical device registration guideline EDREX: GL.CAMD.002, the list of reference countries contains 37 countries, mainly including:
- The 27 EU member states;
- The United Kingdom;
- The United States;
- Canada;
- Australia;
- New Zealand;
- Japan;
- Switzerland;
- Norway;
- Iceland;
- Liechtenstein.
China is not among the 37 reference countries listed in the guideline.
For imported medical devices from non-reference countries, the EDA will impose corresponding requirements for a Free Sale Certificate (FSC) issued by a reference country and for specialist scientific committee review, depending on the product class and the submission pathway.
Key points to note:
- For products from non-reference countries, the complete registration dossier usually requires an FSC issued by a reference country;
- In the initial documentation pathway for non-sterile Class IIa products, the guideline provides a phased arrangement for the FSC: the FSC from the country of origin may be submitted first, and the FSC from a reference country may be supplemented within the prescribed 6 months;
- Class IIb and III products should prepare reference-country FSCs as required by the guideline; the phased arrangement for Class IIa should not be applied directly to high-risk products;
- New registrations, re-registrations, and changes of manufacturing site or country of origin should each be checked against their applicable requirements.
In addition, the IVD registration guideline has its own definition of reference countries; the 37-country list for general medical devices cannot be applied directly to IVDs.
Legal basis: EDREX: GL.CAMD.002, Articles 2, 4.2 and 5 and Annex 1; EDREX: GL.CAMD.001.
3. Fees, Documents and Registration Timelines
Q7 What official fees are involved in Egyptian medical device registration and import?
Answer: For official Egyptian fees, the statutory fee schedule in Schedule 1 of Prime Minister Decree No. 777/2020 can be used as the baseline reference. The main items include:
| Fee item | Statutory fee baseline |
|---|---|
| Medical device registration application (imported) | EGP 7,000 |
| Medical device registration application (locally manufactured) | EGP 5,000 |
| Medical device import licence (invoice value below EGP 10,000) | EGP 500 |
| Medical device import licence (invoice value EGP 10,000-50,000) | EGP 1,000 |
| Medical device import licence (invoice value above EGP 50,000) | EGP 2,000 |
| Customs clearance release application | EGP 500 |
| Scientific office licence | EGP 50,000 |
| GMP inspection | EGP 5,000 per production line; recognised compliant production lines are charged at the EGP 3,000 standard |
Legal basis: Prime Minister Decree No. 777/2020, Schedule 1.
Q8 What core documents are required for Egyptian medical device registration?
Answer: The following documents are usually required for imported medical devices:
1. Applicant and authorisation documents
- Proof of payment of the registration and re-registration fees;
- Commercial registration and importer licence of the Egyptian applicant;
- Authorised representative documents of the applicant;
- A registration authorisation letter issued by the legal manufacturer;
- A duly legalised distribution or agency contract;
- Where necessary, evidence of the relationship between the foreign manufacturer and the foreign supplier.
2. Product quality and free sale certificates
Depending on the product source and the submission pathway, prepare:
- FSC (Free Sale Certificate);
- FDA CFG (Certificate to Foreign Government), where applicable;
- CE certificate;
- ISO 13485:2016 certificate;
- DoC (Declaration of Conformity).
There is a very important distinction here:
An FDA CFG can serve as an alternative to the FSC. Where a qualifying FDA CFG is submitted, a CE certificate is not additionally required; where the CFG expressly states that the manufacturing site complies with the currently applicable GMP requirements, the ISO 13485 certificate may also be waived. If the CFG does not contain the above GMP statement, the corresponding quality system evidence must still be prepared in line with the guideline.
In addition, a CE certificate is not required for non-sterile Class I medical devices.
3. Product technical documentation
- Certificates of raw material composition;
- Physicochemical and biological analysis documents of the product;
- Sterilisation certificates (applicable to sterile products);
- Packaging materials and the quantity per package;
- Inner and outer label information and packaging design drafts;
- Product catalogue;
- Original IFU;
- Evidence of product shelf life and storage conditions;
- Product samples (provided as applicable);
- For non-sterile Class I products, the essential requirements checklist and the list of harmonised standards.
4. Certificate validity and legalisation
As a general rule, the remaining validity of the relevant certificates at the time of submission should be no less than 3 months. For quality certificates issued by reference countries, if the EDA can verify their authenticity with the issuing body, chamber of commerce and Egyptian embassy legalisation may be waived under the guideline; where authenticity cannot be verified, legalisation should be completed as required.
Note also that the EDA whitelist facilitation mechanism (NP.CAMD.005) makes special arrangements for companies on the whitelist, for example a valid FSC is not required to have at least 3 months of remaining validity, and samples may be provided as required by the scientific committee. Therefore, the general rules cannot be applied indiscriminately to whitelist companies.
Legal basis: EDREX: GL.CAMD.002, Annex 1; EDREX: NP.CAMD.005, second edition.
Q9 What are the official review timelines for Egyptian medical device registration?
Answer: According to the EDA registration guideline, the registration process sets out standard and fast-track review timelines. The main milestones are as follows:
| Review milestone | Standard pathway | Fast-track pathway |
|---|---|---|
| Initial acceptance response | 5 working days | 3 working days |
| Technical review and deficiency letter | 20 working days | 7 working days |
| Company response to deficiencies | 60 working days | Completed as required |
| Suspension handling | Up to 90 working days | As per the applicable process |
Note that:
- The fast track should not be understood as granted automatically simply because a CE certificate is held;
- The above timelines mainly reflect the review milestones set out in the guideline and do not represent the total project period from dossier preparation to certificate issuance;
- Specialist committee review, stability and biocompatibility assessments for products from non-reference countries may extend the actual project timeline;
- Time for company responses, document legalisation and coordination with the local applicant should also be built into the project plan.
Legal basis: EDREX: GL.CAMD.002, Article 4.1 and the related flow charts.
Q10 Does Egypt allow submitting part of the documents first and completing the full registration dossier later?
Answer: Yes, provided the corresponding product class and submission conditions are met.
For imported non-sterile Class IIa, IIb and III medical devices, the EDA guideline provides an initial documentation pathway. The initial documents usually include:
- DoC;
- CE certificate;
- ISO 13485 certificate;
- FSC.
After obtaining the initial acceptance number, an import licence may be applied for under the guideline. The complete dossier must then be completed within the prescribed 18 months, of which the main document requirements should be completed within the first 6 months.
Even after the complete dossier has been submitted and formal acceptance obtained, the subsequent import periods must still be managed under the guideline; the initial acceptance number must not be understood as a permanently valid registration licence.
Egyptian local manufacturers have their own corresponding document supplement and transition arrangements; the initial documentation pathway for imported products cannot be copied directly to local manufacturers.
Legal basis: EDREX: GL.CAMD.002, Article 4.2 and the corresponding flow charts.
Q11 Can one registration number cover multiple models or specifications?
Answer: This depends on the actual differences between the products.
The following should normally be checked:
- Trade name;
- GMDN or UMDN code;
- Product classification;
- Intended use;
- Legal manufacturer and actual manufacturing site;
- Product materials and construction;
- Intended user population and scope of use.
If the above core information is identical and there are only specification variations that do not constitute substantive differences, whether they can be included in the same registration application should be judged in line with the guideline and the assessment requirements of the scientific committee.
For Systems or Bundling, the EDA has specific requirements:
| Submission type | Specific requirements |
|---|---|
| System submission | In principle, manufactured by the same legal manufacturer; documents such as the FSC, CE, FDA CFG or DoC should demonstrate that the products belong to one system; assessment is required based on the functional complementarity of the products and the requirements of the relevant specialist committee. |
| Bundling submission | Must meet requirements on manufacturer, classification, generic name, intended use and design similarity; whether the products can be included under one registration number is still determined by the specific product differences and the EDA’s review opinion. |
Therefore, it is not advisable to assume that combined registration is possible simply because the models are similar or belong to the same product family.
Legal basis: EDREX: GL.CAMD.002, Article 11 and the requirements for system and bundling submissions.
Q12 How long is an Egyptian medical device registration certificate valid, and when must it be renewed?
Answer: A general medical device registration certificate is valid for 10 years, counted from the date of registration.
Re-registration must be submitted and obtain initial acceptance within the first 3 months of the final year of the certificate’s validity.
For products that have already entered the re-registration process, the guideline allows the remaining requirements to be completed within a prescribed period after certificate expiry; re-registration requirements should normally be completed within 1 year after expiry, and qualifying products may continue to be sold during that period. If not completed beyond the prescribed period, the matter should be handled as required by the EDA, and the original certificate can no longer be relied upon.
IVDs are different: the marketing authorisation is valid for 5 years; see Q19 for the renewal requirements.
Legal basis: EDREX: GL.CAMD.002, Articles 9 and 10; EDREX: GL.CAMD.001, Article 3.
4. Import, Labelling and Promotion
Q13 Can products be imported directly once the registration certificate is obtained?
Answer: No. Product registration, import licensing and customs clearance release are separate steps in Egypt.
Importing general medical devices mainly involves:
- Obtaining the product registration notification or qualifying initial acceptance documents;
- Applying for an import licence according to the import arrangements;
- An import licence is usually valid for 1 year from the date of issuance;
- For qualifying products with stable import volumes, an annual import plan may be applied for;
- After the goods arrive at the port, the corresponding customs clearance release procedures must still be completed based on the invoice or the annual import plan.
The annual import plan is valid for 1 year; the guideline states that the plan does not limit import quantities, but a separate customs clearance release must still be processed for each commercial invoice. For products not covered by the annual import plan, an import licence must still be applied for under the applicable rules.
Therefore, the 1-year import licence, the annual import plan and per-shipment customs clearance release must not be confused with one another.
Legal basis: EDREX: GL.CAMD.007, second edition, Articles 4 and 5 and the related annexes.
Q14 Must Egyptian medical device labels be in Arabic? Can labelling be done after arrival at the port?
Answer: According to the EDA labelling guideline, the label language may be Arabic or English, provided that the relevant users can understand the product information.
Note that the 2026 UDI guideline imposes separate Arabic requirements on the UDI database information for home-use devices; the two must not be confused. For the exact labelling and IFU language requirements for home-use and non-professional-use products, refer to the current labelling guideline and verify clause by clause before submission.
Regarding relabelling after import:
- Products should meet the EDA’s minimum labelling information requirements at the time of import;
- Handling of the country-of-origin information and the Egyptian importer information should follow the procedures approved by the competent authority;
- Labelling requirements must not be circumvented by covering the original information or creating inconsistent label information;
- Any change to the label information should be handled in accordance with the EDA’s relevant change requirements.
Therefore, companies are advised not to treat arbitrary relabelling or covering of labels after arrival at the port as a routine compliance solution.
Legal basis: EDA Guideline on Labelling Requirements for Medical Devices, Medical and Laboratory Equipment, IVDs and Production Inputs, 24 January 2022.
Q15 What information must Egyptian medical device labels contain? Has UDI become mandatory?
Answer: Medical device labels should present the following information according to the nature of the product and the applicable requirements:
| Information category | Label information |
|---|---|
| Product information | Product name and trade name; model, REF or product code; lot number or serial number; manufacturing date, expiry date or shelf-life information; storage conditions and special handling requirements; single-use indication (where applicable); UDI (per the applicable implementation requirements). |
| Manufacturer information | Manufacturer name; manufacturer address; country of origin. |
| Sterile product information | Sterile indication; sterilisation method. |
| Egyptian importer information | Name of the Egyptian import company; address as recorded in the importer’s registration documents. |
In addition, the EDA has issued the second edition of the UDI guideline:
- Document code: EDREX: GL.CAMD.005;
- Version: 02/2026;
- Publication date: May 2026.
The guideline covers medical devices, accessories and IVDs, and addresses requirements for UDI-DI, UDI-PI, label carriers, direct marking, the UDI database, software as a medical device, implantable devices, systems and accessories.
Special attention: the EDA’s second edition UDI guideline expressly states that the specific implementation dates for UDI carriers on product labels and for direct marking of reusable devices will be announced separately after the market system is established. Therefore, it cannot simply be stated that all device classes have become fully mandatory on the same date. Companies should prepare UDI coding and data management in advance, and continue to monitor the EDA’s follow-up implementation announcements.
Legal basis: EDREX: GL.CAMD.005, second edition; EDA labelling requirements guideline.
Q16 Does advertising and promotion of medical devices in Egypt require prior approval?
Answer: Yes.
The EDA medical device registration guideline expressly requires that written approval from the competent EDA department be obtained before any medical device advertisement is published in any media.
When carrying out product publicity and promotional activities in Egypt, companies should incorporate advertising content approval into their post-market compliance management, and avoid publicity content that exceeds the approved intended use of the product or is inconsistent with the registration documents.
Legal basis: EDREX: GL.CAMD.002, Article 11 and related provisions.
5. Changes, Post-market Obligations and Special Requirements
Q17 After registration in Egypt, how should a site change, a label change or the addition of models be handled?
Answer: This is the key content to be updated in this article.
In November 2026 the EDA published the fourth edition of EDREX: GL.CAMD.003, which governs changes to the data of registration notifications for imported medical devices holding international quality certificates.
The fourth edition provides a more detailed classification of changes to the applicant, manufacturer information, product materials, intended use, design and software, and adds a standalone Case Study documentation pathway.
Therefore, the three general categories in the previous third edition can no longer be used alone to judge whether all changes may be implemented first and whether sales may continue.
The main changes and the approach for handling them are as follows:
| Change category | Specific situations and requirements |
|---|---|
| Change of applicant | For example, transferring the registration notification from one registered import company to another qualifying import company, or to a scientific office, requires submission of a change file. Where the guideline conditions are met, a 3-month circulation period is granted after the initial acceptance number is obtained, and an additional 3-month period may be requested as prescribed. |
| Change of applicant name or address | Where the commercial registration, tax and other entity qualification conditions are met, a change file may be submitted under the fourth edition. A 3-month circulation period is usually granted, and an additional 3-month period may be requested as prescribed. |
| Partial changes not involving design or intended use | For example: a change of raw material, substance or component supplier with unchanged material specifications; adding or replacing a material number for logistics reasons without changing the material itself; process validation after manufacturing process improvement or production scale-up. Where the corresponding conditions are met, the guideline provides for a 1-year circulation period after the initial acceptance number is obtained, and an additional 6-month period may be requested as prescribed. |
| Change of manufacturer name, address and manufacturing site | Changes of manufacturer name, address and legal form, as well as relocation or addition of manufacturing sites, should be filed under the specific categories of the fourth edition. Some of these changes may be granted a 1-year circulation period, and an additional 6-month period may be requested as prescribed. |
| Intended use and design changes | A distinction must be made between non-substantial and substantial changes: non-substantial use restrictions, such as limiting or deleting some indications or narrowing the target patient population, may qualify for the corresponding transition period where conditions are met; substantial changes, such as adding new indications, expanding clinical use, changing the user population, or converting single use to reuse, do not enjoy the general circulation grace period and may only circulate after final approval has been obtained, in accordance with the approved content; changes to design, software and materials must also be judged against the specific examples and risk impacts listed in the fourth edition. |
| Case Study pathway | For design, intended use, software, substance or material changes not listed in the regular change categories, the fourth edition provides for submission for assessment under the Case Study pathway. Different categories of case study files have different circulation periods and subsequent approval requirements; the transition periods for regular changes cannot be applied directly. |
The fourth edition also adjusted the review milestones for change files. The main timelines are as follows:
| Review milestone / requirement | Timeline or outcome |
|---|---|
| Initial receipt of documents and response | 10 working days on the standard pathway and 7 working days on the fast track; |
| Technical assessment of the change file | 25 working days on the standard pathway and 10 working days on the fast track; |
| Company response to deficiencies | Normally completed within 60 working days; |
| Review of the supplementary materials | 25 working days on the standard pathway and 10 working days on the fast track; |
| Number of deficiency rounds and time limit | Five consecutive deficiency rounds, or failure to complete the responses within the prescribed 90 working days (whichever occurs first), may lead to rejection of the application or a request to re-apply. |
For matters not listed in the regular change categories and routed to the Case Study pathway, the fourth edition sets separate handling timelines: qualifying non-substantial changes are granted a 45-day circulation period after the initial acceptance number is obtained; substantial changes are not granted any circulation grace and may only circulate after final approval. Acceptance and assessment of case study files also have separate timelines and must not be mixed with the regular change process.
Practical reminder: the scope of application and the specific product conditions of this edition of the guideline need to be verified item by item, especially changes of applicant, changes of manufacturing site, substantial design changes and intended use changes. Before implementing any change, companies should first complete the classification assessment, and then arrange the change application and the subsequent production, import and sales.
Legal basis: EDREX: GL.CAMD.003, fourth edition, November 2026.
Q18 What mandatory post-market obligations apply in Egypt, and what are the adverse event reporting deadlines?
Answer: According to the Guideline on the Egyptian Medical Devices Vigilance System issued by the EDA in November 2025, manufacturers and the relevant economic operators must establish post-market surveillance and vigilance mechanisms.
The main obligations include:
1. Post-market surveillance
Manufacturers should establish, implement and continuously update a PMS system, collect post-market information on product quality, safety and performance, and take the necessary corrective or preventive actions based on the results.
2. Safety documentation
| Product class and conditions | Safety documentation requirements |
|---|---|
| Class I and Class IIa products with no recalls, FSNs or other regulatory measures in the 3 years before the application | Submit the corresponding Declaration 1 as required by the guideline; |
| Class I and IIa products that have been subject to regulatory measures, and Class IIb and III products | Submit PSURs, national annexes and Declaration 2 as required; |
| IVD Class A and B that have been subject to regulatory measures, and Class C and D products | Fulfil the safety documentation requirements according to the corresponding risk class. |
3. Serious incident reporting
For serious incidents occurring in Egypt, manufacturers should report to the MDSU within the following time limits:
| Incident type | Latest reporting deadline |
|---|---|
| Serious public health threat | 2 calendar days |
| Death or unexpected serious deterioration in health | 10 calendar days |
| Other serious incidents and near incidents | 15 calendar days |
The above periods are counted from the date on which the manufacturer confirms the causal relationship between the incident and its medical device. Where necessary, an initial report may be submitted first, followed by the complete information.
Where the MDSU requires manufacturers, authorised representatives or medical institutions to provide investigation information, the relevant parties should reply within 15 days.
4. PSUR and PMSR
| Product class | PSUR/PMSR requirements |
|---|---|
| Class IIb and III medical devices | PSUR updated and submitted at least annually; |
| Class IIa medical devices | Submitted at least once every 2 years; |
| IVD Class C and D | Submitted at least annually; |
| IVD Class B | Submitted at least once every 3 years; |
| Class I medical devices and IVD Class A | A PMSR is prepared and updated when necessary, and provided to the competent authority as required. |
5. Recalls and field safety actions
Recalls, FSNs, FSCAs and other product safety-related information worldwide should be reported in accordance with the Egyptian vigilance guideline and the applicable procedures.
Therefore, even after the registration certificate is obtained, companies must continue to manage complaints, serious incidents, product recalls, post-market safety reports and related records, and cannot rely passively on the Egyptian importer.
Legal basis: EDREX: GL.CAP.Care.040, first edition, November 2025.
Q19 What is different about IVD registration in Egypt?
Answer: IVDs are governed by the separate guideline EDREX: GL.CAMD.001, first edition, April 2021.
1. Registration classification
The registration guideline adopts the European IVDD classification framework that it references, including:
- List A;
- List B;
- Self-testing;
- General IVD.
The IVD Class A, B, C and D classification used in the 2025 vigilance guideline mainly serves post-market vigilance obligations. The two classification systems must not be confused.
2. Certificate validity
An IVD marketing authorisation is valid for 5 years; renewal applications should be submitted within the last 6 months of the certificate’s validity, together with a summary of the marketing history.
After certificate expiry, re-registration should normally be completed within 1 year; qualifying products may continue to circulate during that period. If not completed beyond that period, there is a further 6-month supplementary period, during which production or import of the product should be suspended.
3. Review and deficiency responses
For imported and locally manufactured IVDs holding international quality certificates:
- The document assessment timeline is 20 working days;
- The deficiency response period is up to 60 working days;
- Where the deficiencies cannot be completed, an additional 30 working days may be requested.
For Egyptian locally manufactured IVDs without international quality certificates, a separate process applies covering factory assessment, pilot production batches, laboratory analysis and document deficiency responses; the deficiency period differs from the international quality certificate pathway, and the 60-working-day requirement cannot be applied directly.
4. Annual import licence
Imported IVDs apply for an annual import licence separately for each foreign manufacturing plant; the guideline states that import quantities are not limited; specific shipments still require the corresponding customs clearance release per invoice.
5. Testing of the first three batches
After the marketing authorisation is obtained, the first 3 batches of manufactured or imported IVDs must complete analytical testing, and may only be released after the test results are qualified.
6. Transition arrangements for products newly entering the market
For IVDs not previously circulated in Egypt, the guideline provides that, where the application conditions are met, they may circulate temporarily for 6 months from the date of the first import licence or the first local production batch, provided that the applicant applies for and obtains the marketing authorisation before that period ends.
Legal basis: EDREX: GL.CAMD.001, first edition, April 2021.
Q20 Which medical devices face rejection or special review requirements in Egypt?
Answer: The EDA registration guideline lists a number of products with explicit restrictions:
| Product | EDA guideline provision |
|---|---|
| Surface-textured breast implants | Registration not accepted |
| Surface-textured tissue expanders | Related registration, import and subsequent procedures not accepted |
| Permanent injectable soft tissue fillers | Not accepted |
| Laparoscopic double-row staplers for the digestive system | New registration and re-registration not accepted |
| Powdered surgical latex gloves | New registration not accepted |
| Steel lancets | New registration not accepted |
| Surgical needles without suture attachment | Expressly not accepted by the guideline |
| Vein, muscle and subcutaneous syringes without needles | New registration and re-registration not accepted |
| Dual-scale syringes | Not accepted for processing |
| Insulin syringes other than the 100-unit specification | Registration not permitted |
In addition, some products require prior special consultation or scientific committee assessment:
- Class I non-sterile otic (ear) products: product information must be submitted, first for the pharmacology committee to determine whether any pharmacological action exists; if not, the products are then submitted to the ENT specialist committee for assessment.
- Class I non-sterile nasal dosage forms: assessment by the pharmacology committee and the relevant specialist committee is required.
- Class I non-sterile oral dosage forms: consultation and committee assessment must likewise be submitted under the corresponding procedures.
- Medical devices for the treatment of obesity: where the product is classified as a medical device in its country of origin, a consultation should be submitted for assessment of its registration status in Egypt by the relevant specialist committee.
These products should not all be simply labelled as ‘prohibited from registration’. For products expressly not accepted, the guideline should be followed; for products requiring special review, the consultation and committee assessment should be completed first, before deciding whether formal registration documents can be submitted.
Legal basis: EDREX: GL.CAMD.002, Article 11 and the special product requirements.
Final thoughts: what really matters for registration in Egypt?
As the 20 questions above show, the key to market access for medical devices in Egypt is not just obtaining the registration certificate, but planning the registration applicant, product registration, import licences, changes and post-market management as one complete process.
For Chinese manufacturers, the following points deserve particular attention:
- China is not among the reference countries listed in the EDA general medical device registration guideline; before registration, confirm the FSC source and the specialist committee review requirements.
- The Egyptian local applicant affects registration, import and subsequent change arrangements; the early registration cost alone should not be the only consideration.
- There are substitution relationships among FDA CFG, CE and ISO 13485 certificates; the applicable pathway should be selected according to the actual product situation.
- The registration certificate is valid for a long period, but registration changes, import licences, labelling and post-market vigilance still require ongoing maintenance.
- The fourth edition of CAMD.003 published in November 2026 provides more detailed rules on change categories, transfer of the applicant and circulation periods; companies should use the latest edition when assessing changes.